Evaluation of in vivo bioequivalence methodology for topical clobetasol 17-propionate based on pharmacodynamic modeling using Chinese skin.
The United States Food and Drug Administration recommends pilot dose duration-response and pivotal bioequivalence studies to be conducted using reflectance colorimetry for assessment of the in vivo bioequivalence of topical dermatologic corticosteroids. The major objectives of the present studies were to examine the applicability of the standardized pharmacodynamic modeling-based methodology to super-potent clobetasol 17-propionate (CP) in the Chinese population and to evaluate the bioequivalence of two generic ointments and four generic creams containing 0.05% (w/w) CP with respect to Dermovate formulations using such methodology. In the pilot dose duration-response study, although the E(max) model (where E(max) is the maximum fitted value of AUEC, which is the area under the baseline-corrected, untreated control-site-corrected a* scale data from 0 to 24 h after drug removal) did not provide acceptable model fits, E(max) parameter estimates of -38.97 +/- 3.62 and -41.89 +/- 11.28 a*-scale. h, and ED(50) (dose duration required to achieve 50% of the fitted E(max) value) estimates of 0.40 +/- 0.37 and 0.42 +/- 0.16 h were obtained for Dermovate ointment and cream, respectively, by population analyses. The estimates for the two formulations were not statistically different, so in vivo bioequivalence studies were conducted at an ED(50)dose duration of approximately 0.5 h for both Dermovate formulations. The results demonstrated that one generic ointment was bioequivalent to Dermovate, whereas the other was not. None of the generic creams were shown to be bioequivalent to Dermovate cream. The in vivo bioequivalence data from the vasoconstriction assay were linearly correlated with stratum corneum uptake of the drug at the same dose duration until the maximal vasoconstriction response was achieved. The studies illustrated the applicability of the standardized pharmacodynamic modeling-based methodology in detecting the product differences between a variety of generic 0.05% CP formulations and reference Dermovate formulations in Chinese skin.
Tsai
Jui-Chen
JC
Institute of Clinical Pharmacy, College of Medicine, National Cheng Kung University, Tainan, 1 University Road, Tainan, Taiwan 70101. jctsai@mail.ncku.edu.tw
Cheng
Ching-Ling
CL
Tsai
Yi-Fang
YF
Sheu
Hamm-Ming
HM
Chou
Chen-Hsi
CH
D000287:Administration, Topical; D044466:Asian People; D001499:Bayes Theorem; D002626:Chemistry, Pharmaceutical; D002990:Clobetasol / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D016001:Confidence Intervals; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D008954:Models, Biological; D017711:Nonlinear Dynamics; D009824:Ointments / Q000008:administration & dosage / Q000493:pharmacokinetics; D010865:Pilot Projects; D012867:Skin / Q000187:drug effects* / Q000378:metabolism; D013810:Therapeutic Equivalency; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology
D009824:Ointments; D002990:Clobetasol